ANAPHYLAXIS AFTER TREATMENT WITH RECOMBINANT FACTOR-VIII

Background: Treatment of hemophilia patients with recombinant factor V III concentrates has not previously been associated with anaphylaxis. Study Design and Methods: A 5-week-old boy with severe hemophilia A de veloped dyspnea, cyanosis, hypotension, and a diffuse urticarial rash following treatment with a recombinant factor VIII (Recombinate). To i dentify the cause of anaphylaxis in this patient, the vial lot was exa mined for the presence of endotoxin, and a checkerboard immunoblotting technique was used to test serum and/or plasma samples from the patie nt and mother for the presence of antibodies (IgA, IgG, IgE, and IgM) to Recombinate-related antigens (recombinant factor VIII, von Willebra nd factor, human serum albumin, Chinese hamster ovary proteins, bovine serum albumin, mouse monoclonal anti-human factor VIII, polyethylene glycol 3350), and to ethylene oxide, the agent used to sterilize the i nfusion equipment. Results: No immune response directed against the Re combinate-related antigens or ethylene oxide that could be associated with the anaphylactic reaction was identified. Endotoxin was not prese nt upon rabbit pyrogen testing of the therapeutic product. Conclusion: These studies failed to show any association between Recombinate and the onset of the allergic reaction, This seems to be the first reporte d case of anaphylaxis following the infusion of a recombinant form of factor VIII concentrate.